Compare TAP & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TAP | ALKS |
|---|---|---|
| Founded | 1873 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 8.7B |
| IPO Year | 1994 | 2012 |
| Metric | TAP | ALKS |
|---|---|---|
| Price | $41.42 | $47.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 14 |
| Target Price | ★ $48.94 | $43.43 |
| AVG Volume (30 Days) | ★ 2.6M | 1.4M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.53% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.03 | N/A |
| Revenue | ★ $11,723,800,000.00 | $1,475,899,000.00 |
| Revenue This Year | $0.85 | $24.26 |
| Revenue Next Year | $0.17 | $4.47 |
| P/E Ratio | $20.52 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $38.04 | $25.17 |
| 52 Week High | $54.82 | $55.67 |
| Indicator | TAP | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 49.44 | 40.85 |
| Support Level | $40.53 | $47.66 |
| Resistance Level | $41.76 | $51.25 |
| Average True Range (ATR) | 0.96 | 1.41 |
| MACD | -0.12 | -0.12 |
| Stochastic Oscillator | 33.69 | 9.75 |
Molson Coors owns well-known beer brands including Miller, Coors, Blue Moon, and Carling, and ranks as the second-largest beer maker in both value and volume in the US, Canada, and the United Kingdom. Through licensing agreements, it also brews and distributes beer and nonbeer beverage categories under partner brands from Heineken, Anheuser-Busch InBev, Asahi, Fever-Tree, and Coca-Cola. North America remains its largest market, accounting for nearly 80% of total revenue.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.